We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+1.2%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$1.79B
AUM Growth
-$552M
Cap. Flow
-$341M
Cap. Flow %
-19.04%
Top 10 Hldgs %
44.27%
Holding
146
New
11
Increased
19
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.9M
2
AGEN
Agenus
AGEN
+$27.2M
3
RVMD icon
Revolution Medicines
RVMD
+$21.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.3M
5
VOR icon
Vor Biopharma
VOR
+$11.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$53M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$47.9M
3
BLU
BELLUS Health Inc.
BLU
+$21.4M
4
ONC
BeOne Medicines Ltd
ONC
+$9.17M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$7.88M

Sector Composition

Rank Sector Weight
1 Healthcare 92.03%
2 Consumer Discretionary 3.74%
3 Real Estate 0.39%
4 Financials 0.33%
5 Industrials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
26
CALL
BeOne Medicines Ltd
ONC
$33.9B
$22M 1.23%
100,000
+50,000
+100% +$9.17M
RLAY icon
27
Relay Therapeutics
RLAY
$4B
$21.7M 1.21%
1,454,716
– –
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$21.4M 1.2%
1,000,000
+250,000
+33% +$5.34M
KURA icon
29
Kura Oncology
KURA
$793M
$21.1M 1.18%
1,700,000
+600,000
+55% +$8.72M
WVE icon
30
Wave Life Sciences
WVE
$1.12B
$21M 1.17%
3,000,000
– –
ERAS icon
31
Erasca
ERAS
$6.15B
$20.3M 1.13%
4,710,682
+1,538,461
+48% +$10.4M
VOR icon
32
Vor Biopharma
VOR
$1.06B
$19.1M 1.07%
143,779
+116,279
+423% +$11.5M
REPL icon
33
Replimune Group
REPL
$454M
$19M 1.06%
700,000
-200,000
-22% -$4.16M
SDGR icon
34
Schrodinger
SDGR
$1.13B
$13.1M 0.73%
700,000
– –
OMGA
35
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$13M 0.72%
2,273,530
– –
MRSN
36
DELISTED
Mersana Therapeutics
MRSN
$12.9M 0.72%
88,000
– –
BEKE icon
37
CALL
KE Holdings
BEKE
$17.7B
$11.2M 0.62%
+800,000
New +$11.1M
RNAM
38
DELISTED
Avidity Biosciences
RNAM
$11.1M 0.62%
500,000
+250,000
+100% +$3.73M
GBIO
39
DELISTED
Generation Bio
GBIO
$11.1M 0.62%
281,419
– –
FHTX icon
40
Foghorn Therapeutics
FHTX
$278M
$11M 0.61%
1,720,720
– –
TVTX icon
41
Travere Therapeutics
TVTX
$5.17B
$10.5M 0.59%
+500,000
New +$10.6M
RPTX
42
DELISTED
Repare Therapeutics
RPTX
$10.3M 0.57%
700,000
– –
INSM icon
43
Insmed
INSM
$22.4B
$9.99M 0.56%
+500,000
New +$9.66M
NTLA icon
44
Intellia Therapeutics
NTLA
$1.51B
$9.6M 0.54%
275,000
– –
EVO icon
45
Evotec
EVO
$686M
$9.3M 0.52%
1,149,425
– –
SE icon
46
Sea Limited
SE
$66.4B
$8.97M 0.5%
172,500
– –
ALPN
47
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.77M 0.49%
1,193,030
– –
NTRA icon
48
Natera
NTRA
$36.4B
$8.03M 0.45%
200,000
+100,000
+100% +$4.12M
ITOS
49
DELISTED
iTeos Therapeutics
ITOS
$7.81M 0.44%
400,000
– –
RXRX icon
50
Recursion Pharmaceuticals
RXRX
$1.58B
$7.4M 0.41%
960,204
+510,204
+113% +$5M
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q4 2022 Portfolio in Review

As of Q4 2022, Artal Group held 146 positions worth $1.79B, down 24% from $2.34B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group withdrew a net $341M in Q4 2022, closing 17 positions and reducing 12 holdings. Its most notable exit was argenx, an estimated $53M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Real Estate.

Against the trend, Artal Group opened a new position in Revolution Medicines worth $23.8M.

  • Artal Group's largest Q4 2022 buy was Revolution Medicines: 1,000,000 shares worth $23.8M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $32.9M increase.
  • Artal Group's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $21.4M.
  • Artal Group fully exited argenx in Q4 2022, selling an estimated $53M.
  • Artal Group's ten largest holdings make up 44% of its $1.79B portfolio in Q4 2022.
  • Artal Group opened 11 new positions and closed 17 in Q4 2022.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $1.79B.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.